Contributions
Abstract: P413
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Comorbidity
Background: Recent studies have demonstrated the negative effect of vascular disease on disability progression in multiple sclerosis (MS). We analyzed the effect of arterial hypertension (AH) on the rate of disability progression in relapsing-remitting MS (RRMS).
Materials: 595 subjects with RRMS entered the study. Retrospective data from the database of St. Petersburg City center for MS (CCMS) included the patients evaluated every 3 months for 2 to 6 years. Confirmed AH data included i) in-patient questioning, ii) BP and physical examination monitoring data and iii) health care services medical records.
EDSS was calculated by neurologists qualified to evaluate EDSS. Statistical analysis is performed with the program SAS 9.4 considering sex and age data as co-factors.
Results: AH was confirmed in 16.3% (97/595) RRMS patients. In AH(+) patients and AH(-) the period of time of EDSS progression to 3.0, 4.0 and 6.0 was documented. Using the Kaplan-Meier analysis, AH (+) patients revealed significantly more short time to reach established levels of disability compared to those AH(-), i.e. EDSS 3.0 (p 0.002), 4.0 (p 0.02) and 6.0 (p 0.103). These results are confirmed by Cox regression analysis. The risk of progression to score 3.0, 4.0 and 6.0 was higher in AH(+) vs AH(-) patients: RR 1.4, (p 0.016, CI 95% 1.06-1.88), RR 1.74 (p 0.013, CI 95% 1, 12-2.69), and RR 3.4 (p 0.03, CI 95% 1.12-10.48), respectively.
EDSS score progression at 5 and 10 years since the time MS diagnosis was confirmed, using the Wilcoxon and Mann-Whitney test revealed the disability in the AH(+) group increased more significantly than in the group AH(-).
Conclusions: AH appeared to be an independent factor in accelerating the disability progression in patients with RRMS. AH is associated with a higher risk of disability and reaching higher disability score in a shorter time.
Disclosure: Neofidov N.A.: nothing to disclose. Totolyan N.A.: nothing to disclose. Shumilina M.V.: fees for consulting services in the field of scientific and pedagogical activity (educational services, scientific articles, participation in expert councils, participation in research, etc.) from the following companies: Roche, Johnson & Johnson/Janssen, Genzyme/Sanofi, Novartis, Generium, Biocad. Skoromets A.A: nothing to disclose. Evdoshenko E.P.: fees for consulting services in the field of scientific and pedagogical activity (educational services, scientific articles, participation in expert councils, participation in research, etc.) from the following companies: Biogen, Novartis, Johnson, Roche, Sanofi, Jinzyme, Merck, Generium, SIA-AFS, Pharmstandard, Farm Sintez.
Abstract: P413
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Comorbidity
Background: Recent studies have demonstrated the negative effect of vascular disease on disability progression in multiple sclerosis (MS). We analyzed the effect of arterial hypertension (AH) on the rate of disability progression in relapsing-remitting MS (RRMS).
Materials: 595 subjects with RRMS entered the study. Retrospective data from the database of St. Petersburg City center for MS (CCMS) included the patients evaluated every 3 months for 2 to 6 years. Confirmed AH data included i) in-patient questioning, ii) BP and physical examination monitoring data and iii) health care services medical records.
EDSS was calculated by neurologists qualified to evaluate EDSS. Statistical analysis is performed with the program SAS 9.4 considering sex and age data as co-factors.
Results: AH was confirmed in 16.3% (97/595) RRMS patients. In AH(+) patients and AH(-) the period of time of EDSS progression to 3.0, 4.0 and 6.0 was documented. Using the Kaplan-Meier analysis, AH (+) patients revealed significantly more short time to reach established levels of disability compared to those AH(-), i.e. EDSS 3.0 (p 0.002), 4.0 (p 0.02) and 6.0 (p 0.103). These results are confirmed by Cox regression analysis. The risk of progression to score 3.0, 4.0 and 6.0 was higher in AH(+) vs AH(-) patients: RR 1.4, (p 0.016, CI 95% 1.06-1.88), RR 1.74 (p 0.013, CI 95% 1, 12-2.69), and RR 3.4 (p 0.03, CI 95% 1.12-10.48), respectively.
EDSS score progression at 5 and 10 years since the time MS diagnosis was confirmed, using the Wilcoxon and Mann-Whitney test revealed the disability in the AH(+) group increased more significantly than in the group AH(-).
Conclusions: AH appeared to be an independent factor in accelerating the disability progression in patients with RRMS. AH is associated with a higher risk of disability and reaching higher disability score in a shorter time.
Disclosure: Neofidov N.A.: nothing to disclose. Totolyan N.A.: nothing to disclose. Shumilina M.V.: fees for consulting services in the field of scientific and pedagogical activity (educational services, scientific articles, participation in expert councils, participation in research, etc.) from the following companies: Roche, Johnson & Johnson/Janssen, Genzyme/Sanofi, Novartis, Generium, Biocad. Skoromets A.A: nothing to disclose. Evdoshenko E.P.: fees for consulting services in the field of scientific and pedagogical activity (educational services, scientific articles, participation in expert councils, participation in research, etc.) from the following companies: Biogen, Novartis, Johnson, Roche, Sanofi, Jinzyme, Merck, Generium, SIA-AFS, Pharmstandard, Farm Sintez.